Regulatory · Fundamentals
What the peptide panel is really voting on
Peptides have become hard to avoid. A friend has started injecting something for recovery. Your doctor either shrugs or tells you to be careful. The New Yorker, the Times, NPR, Bloomberg, and New York Magazine have all run features in the last year. Ozempic is in every other conversation, and Ozempic is a peptide. The whole category has started the slow walk from the biohacker corner of the internet into everyday health.
The next real moment for that walk is scheduled for July 23 and 24. On those two days, the FDA’s compounding advisory committee will meet in Silver Spring, Maryland, and vote on whether seven peptides should be returned to a list that makes them legal to prescribe. Most of the coverage so far has framed the meeting as a referendum on whether these compounds are coming back. That framing is close. It is also off in a specific way that changes which compounds will actually come back, and for what.
The panel isn’t voting on peptides. It’s voting on indications.
The FDA’s Pharmacy Compounding Advisory Committee is reviewing seven peptides at its July 23–24, 2026 meeting. The committee votes on specific nominated medical conditions, not on a compound’s full range of uses. A positive vote only permits compounding for that evaluated condition. Not for everything else people take the compound for.
On the agenda, next to each compound, the FDA has included a column titled “Uses evaluated.” It lists one or two specific medical conditions per peptide. What the column quietly communicates is that the committee isn’t being asked whether BPC-157 works. It is being asked whether BPC-157 works for ulcerative colitis. If the answer is yes, BPC-157 becomes legally compoundable for that condition, and only that condition. Use it for a shoulder, and the pharmacy is in the wrong.
For most of the seven peptides, the condition on the agenda is not the condition anyone is actually taking the compound for. That gap is most of the story.
The bigger thing this meeting is a step inside
The July 2026 PCAC meeting is the first open regulatory review of research peptides at this scale in the United States. For most of their history, these compounds existed in a legal gray zone with no real prescription pathway. That started changing when GLP-1 drugs like Ozempic brought peptides into mainstream medicine and regulators had to catch up.
Peptides as a category are quietly becoming legitimate medicine in the United States for the first time. For most of their history here, peptides that aren’t Ozempic have lived in a gray zone. You couldn’t buy them at a pharmacy. Your doctor probably couldn’t prescribe them. The research was strong enough to build reputations on but nowhere near funded enough to earn an FDA approval, because most peptides can’t be patented and nobody was going to spend the hundreds of millions an approval costs for a molecule anyone can synthesize.
The GLP-1 drugs broke that pattern. Ozempic, Wegovy, Mounjaro, Zepbound. All peptides. All mass-market. The drug industry, for the first time, had a reason to take this category seriously, and regulators had a reason to catch up. The scale of the shift is easy to see in the numbers. Ozempic’s Google search interest rose twenty-five-fold between early 2021 and its 2024 peak. The generic term “peptides” hit a series high this March, more than eight times its January 2022 level. r/Peptides, the community home for the space, went from roughly five thousand subscribers in early 2020 to a hundred and fifty-six thousand today.
July is the first concrete step in that catching up. It will not produce the dramatic “peptides are back” headline the coverage is predicting, but it is the first regulated, open-session conversation about peptide access to happen at this scale. The seven small questions in front of the committee will shape what legal peptide access in the United States looks like for the rest of the decade.
Who’s in the room
The Pharmacy Compounding Advisory Committee has ten voting seats. Four are filled. Six are empty, and will be filled by temporary experts FDA names in the two weeks before the meeting. Of the four confirmed, one has already voted no on peptides twice. Two represent institutions whose job is to ask for more evidence. The fourth doesn’t vote.
Ten people vote in that room. In April 2026, we only know who four of them are.
None of the four confirmed have published research on therapeutic peptides. Elizabeth Rebello of MD Anderson, the acting chair of the December 2024 session, is an anesthesiologist and pharmacist; she voted no on every peptide she saw that day. Timothy Fensky, a former president of NABP and of the Massachusetts Board of Registration in Pharmacy, sits in the seat that speaks for state pharmacy regulators. Brian Serumaga of the United States Pharmacopeia runs the expert committee that writes the quality standards for compounding; none of the seven July compounds have USP monographs, which is the specific thing he is institutionally paid to notice. Donnette Staas of Jazz Pharmaceuticals holds the industry representative seat and doesn’t vote. Six seats remain open. This is not a knock on the committee’s competence. It is a description of the institutional gap: a panel of careful professionals is being asked to evaluate a class of compound outside any of their professional reach.
FDA fills the remaining seats through the Special Government Employee rule, an internal pre-vetted database of topical experts the Commissioner can appoint for a single meeting, with no public nomination process and no Federal Register notice. The names become public in two places before July 23. Financial-conflict waiver filings land at least fifteen days out, which means around July 8 for anyone with a disclosed interest in the substances under review. The full meeting roster posts with the briefing materials two business days before, around July 21. Between those two dates, nothing is announced. With six vacant voting seats and an administration that has publicly named these compounds as a priority, the current HHS leadership has substantial discretion over the composition of the July 2026 majority. The committee that votes in July does not fully exist yet.
The 2024 committee is mostly gone. Of the people who voted in October and December, only Rebello remains. Padma Gulur of Duke Anesthesiology chaired the October session that voted no on AOD-9604, CJC-1295, and Selank. Robin Bogner of the University of Connecticut, whose work on freeze-drying protein therapeutics is the closest technical literacy to peptide formulation this committee has ever had, voted no on Thymosin alpha-1 in December. Allen Vaida, a retired medication-safety specialist, is the single member in the modern PCAC record with a confirmed pro-access vote: he was acting chair at the 2022 meeting that added glutathione to the compounding list against FDA’s own recommendation.
Between now and July 23, the single piece of news that will move the prediction most isn’t a study, a comment, or a leaked briefing. It’s six names. The four confirmed members are what they are, publicly on the record. The six still to be named will be chosen by HHS, whose Secretary has publicly said he wants these compounds legal. Whose majority lands in the room is the July question, and the two dates that answer it are July 8 and July 21.
Who’s betting on this
The commercial infrastructure was already moving before the vote was scheduled. Hims purchased a California peptide manufacturing facility in February 2025. Compounding pharmacies that testified at 2024 PCAC hearings later sued the FDA. A Florida biotech’s March 2026 SEC filing named nine Kennedy-list peptides by compound, putting the regulatory story inside formal shareholder disclosures more than a year before any vote.
The commercial side has already started moving. People with money at stake have decided something is coming, and they aren’t waiting for the vote.
Hims, the public telehealth company behind the commercials you’ve probably seen, bought a California peptide manufacturing facility in February 2025, more than a year before the vote. The compounding pharmacies that argued for these peptides at the 2024 committee hearings (two of which turn out to share a CEO) sued the FDA that year and again in 2025. And the stock market has started writing Kennedy’s fourteen-peptides line into its own paperwork: a Florida biotech’s annual report to the SEC, filed in March of this year, named nine of Kennedy’s fourteen peptides by compound. Those fourteen peptides are no longer just something Kennedy said on a podcast. They are inside the filings public companies make to their shareholders.
None of this predicts the vote. It does tell us that peptide-focused medical-education courses are running, major telehealth platforms are advertising peptide services, and the ecosystem that would serve a wider peptide market is already being built, and has been for months.
What the 503A list actually is
The 503A Bulks List is the FDA’s approved list of ingredients that licensed compounding pharmacies can use to fill individual prescriptions. Getting a compound onto that list is not the same as FDA drug approval. It creates a prescription pathway for individual patients, not a commercial product. For most research peptides, it’s the only realistic route to any kind of legal access.
The 503A Bulks List is the FDA’s list of starting ingredients that compounding pharmacies are allowed to use. A compounding pharmacy is a pharmacy that makes a drug to order for a specific patient, rather than selling a factory-made pill in a labeled bottle. If your clinician has ever written you a prescription for a cream or a troche that had to be mixed for you in the back of the pharmacy, you’ve used one.
The list matters because compounding is the only practical route most peptides will ever have to legal access. Peptides are hard to patent in ways that would make a full drug-approval trial pay off. A few of the seven have patents on specific formulations, and TB-500 actually has a late-stage trial running at a small company called RegeneRx, though for dry eye, not for the kind of wound healing the FDA is reviewing here. Nobody is lined up to bring any of the seven to market the way Novo Nordisk brought Ozempic. The only way a doctor can write you a legal prescription for most peptides is if the raw ingredient is on the list.
There are two events to keep straight. The first was the April 15, 2026 Federal Register notice (FR 2026-07361), which removed the seven July compounds from the Category 2 restricted list and cleared the path for PCAC review. The committee vote in July is the second. A yes vote moves the compound into the FDA’s interim “Category 1” status within weeks to months, which is the practical moment pharmacies can start compounding it. The formal rule, which makes that status permanent, comes later.
And that compounding is only authorized for the specific indication FDA evaluated. Which is the piece most of the coverage is missing: FDA chose what the committee votes on.
For BPC-157, FDA chose “ulcerative colitis.” Not “gut health,” not “inflammation,” not “tissue repair.” Ulcerative colitis. For KPV, FDA chose “wound healing and inflammatory conditions,” which covers an enormous range of patients. Same meeting, same committee, completely different ceiling. The committee can vote narrower than FDA chose. It cannot practically vote broader. The fate of each compound was shaped before the meeting opened.
In theory, FDA could override all of this and approve on broader terms than the committee evaluated. In practice, the agency has stayed within the phrase it first chose. Until that changes, the phrase is the ceiling, and the pharmacist can only fill for the use inside it. That last sentence is most of the article.
The seven compounds, ordered by whether a yes vote actually helps the people currently taking them
The seven July compounds vary a lot in how much a positive vote would actually help the people currently taking them. The key variable isn’t how likely a compound is to pass. It’s whether the FDA-nominated condition matches what people are actually using it for. KPV and DSIP have the strongest match. BPC-157 and TB-500 have the weakest.
None of the seven peptides below can be legally compounded in the United States right now. They are all sitting in the restricted category the FDA placed them in during 2023. The people who take them today get them from gray-market suppliers and inject them following forum instructions.
Before the walkthrough, one quick look at what the evidence base actually looks like across the seven.
| Dimension | KPV | Semax | DSIP | BPC-157 | TB-500 | MOTs-C | Epitalon |
|---|---|---|---|---|---|---|---|
| Registered human trials | 0 | 1 | 0 | 2 | 19 | 3 | 0 |
| Trials on FDA indication | 0 | 0 | 0 | 0 | 5 | 1 | 0 |
| PubMed papers 2015–2025 | 52 | 89 | 14 | 147 | 213 | 104 | 31 |
| NIH grants (count) | 0 | 0 | 0 | 0 | 8 | 2 | 0 |
For each compound below, two questions. If a yes vote happens, who actually gets legal access: the people already taking the compound through gray-market channels, a far wider population for whom the approved indication opens a new door, or both? And how likely is the vote itself to go yes?
KPV injection for inflammation and IBD
KPVis a three-amino-acid fragment of a skin-pigmentation hormone. Current gray-market use is mostly for inflammatory bowel conditions (Crohn’s, ulcerative colitis), inflammatory skin conditions, and general inflammation. The mechanism is well-characterized. What is thin is the human evidence: more than fifty preclinical publications exist, almost all in animal models of colitis or cell culture, and zero registered human clinical trials anywhere in the world.
The FDA’s indication on the agenda is “wound healing and inflammatory conditions.” That phrase is unusually broad. A patient walking into a compounding pharmacy post-approval could plausibly qualify by citing almost any documented inflammatory condition: Crohn’s, UC, eczema, psoriasis, inflammatory arthritis, a wound that isn’t healing.
If the vote passes, most current users can legally get KPV for the reasons they’re already taking it. The FDA’s broad indication also opens legal access to a much larger population: patients with any documented inflammatory condition, including plenty who have never touched the gray market. Of the seven compounds on the agenda, KPV is the likeliest to pass.
Semax nasal spray for cognitive performance
Semax has been a prescription medication in Russia since 1996. It is a nasal spray used there for cognitive-performance and neurological conditions. Outside Russia, most Americans take it for focus, verbal fluidity, the kind of effects people describe as clearing the fog.
The FDA is evaluating it for three specific neurological conditions: cerebral ischemia, migraine, and trigeminal neuralgia. A patient walking in with a documented migraine history has a clean prescription path. Someone who wants Semax to focus at work has no qualifying story.
The Russian evidence base is thinner than the “thirty years of Russian clinical use” framing suggests. Of the five international trial registries we checked, only one holds a registered Semax trial: a 2022 study on COVID-19 chemosensory dysfunction, not the three conditions the FDA is actually reviewing. The older Russian clinical literature exists in academic publications, not in a registry system the committee would treat as primary evidence.
If the vote passes, the nootropic-user population, which is most current gray-market use, still cannot legally get Semax. But migraine sufferers can, and migraine affects tens of millions of Americans: a far larger population than anyone currently using Semax through unofficial channels. The vote itself is close.
DSIP injection for sleep
DSIPstands for Delta Sleep-Inducing Peptide. It was first isolated in 1974. Current community use is almost entirely for sleep. People take it because they’re not sleeping well, or they sleep but wake up unrecovered, or they wake up at 3am and can’t get back down.
The FDA is evaluating it for three indications: opioid withdrawal, chronic insomnia, and narcolepsy. “Chronic insomnia” is the one that matters. A patient who can truthfully say “I’ve been sleeping poorly for the last several weeks” qualifies. Most current DSIP users could get it legally without changing a word of how they describe their situation.
The gap is evidence. Zero registered human clinical trials exist for DSIP in any international registry. The published work is thin and mostly European from the 1980s.
If the vote passes, most current users can legally get DSIP. The “chronic insomnia” indication is broad enough that legal access also extends to the much larger insomnia population: people with sleep problems who have never tried peptides. The vote itself is leaning no, though, on evidence. The indication match is strong. The record in front of the committee is thinner than what recent peptide nominations have cleared.
BPC-157 injection for tendon and joint injury
Somewhere out there is a reader who’s been injecting BPC-157for a torn shoulder for two years, following a protocol they pieced together from Reddit threads and a supplier they’ve never met. By the agenda’s own wording, the July vote is not about them. This is also the compound most of the coverage is really about, and the one the coverage is most misleading about.
BPC-157 is a chain of fifteen amino acids from a protein in human gastric juice. It has more than a hundred published rodent studies on tendon healing, joint recovery, gut protection, and inflammation. Human clinical evidence is thin: the global trial registries return two studies, one on a muscle injury and one on pharmacokinetics, and neither is on ulcerative colitis.
When we pulled nearly two thousand Reddit posts and comments about BPC-157 and classified them, the shape was stark. Tendon and joint injuries were by far the most common topic. Ulcerative colitis came up rarely in the wider community, though it matters a great deal to the patients who actually have it. And the gap between the two is widening fast.
Every year, more of the community is taking BPC-157 for something the FDA isn’t asking about.
The community’s dominant combination is the BPC-157 plus TB-500 pairing, sometimes called the Wolverine stack. Two-thirds of BPC-157 posts also reference TB-500. Four in five TB-500 posts mention BPC-157. The two peptides are used together for exactly the kind of tendon and joint healing that is not on the agenda for either one.
The FDA is evaluating BPC-157 for ulcerative colitis only. A UC patient walking into a post-approval compounding pharmacy with a documented diagnosis has a clean prescription path. A patient with a torn Achilles has none.
The UC indication is not arbitrary, though. In the same corpus, r/UlcerativeColitis is the single most positive community on BPC-157. Among UC patients who tried it and reported a result, roughly seventy percent said it worked, a rate higher than any of the musculoskeletal-focused communities. The committee has a real patient-reported signal to work with. What it does not have is a registered UC trial of BPC-157 to put next to that signal.
If the vote passes, only UC patients can legally get BPC-157. That is a real population of roughly one million Americans, and most of them have never touched a peptide. But the musculoskeletal-injury use, which is almost all current gray-market use and the largest patient base the compound could plausibly serve, is still locked out. And the vote itself is leaning no.The committee’s 2024 record on peptide nominations is clear, and the UC-specific case is not obviously stronger than those were.
TB-500 injection for injury recovery
TB-500 is the active fragment of Thymosin Beta-4, one of the most abundant proteins in mammalian tissue. Most of the human research on it has looked at heart-attack recovery and, more recently, corneal and skin wounds. Most of the community use is broader: injury recovery, hair, skin, systemic repair, and the Wolverine stack pairing with BPC-157.
The FDA is evaluating it for wound healing. “Wound healing” in FDA parlance typically means dermatological or surgical, not musculoskeletal soft-tissue injury. A patient with a chronic non-healing skin wound or a slow surgical recovery has a plausible path. A patient with a pulled hamstring or a strained rotator cuff does not.
TB-500 has the richest registered trial base of any compound on the agenda. Nineteen trials globally, including five that address wound-healing indications directly. That is the strongest evidence-to-indication match on the entire meeting, on paper.
If the vote passes, chronic skin-wound and post-surgical patients can legally get TB-500. That is a real new population, even if it is a fraction of the injury-recovery and systemic-repair use base that most current users take it for. And the vote is leaning no.
MOTs-C injection for metabolic health
MOTs-Cis unusual because it is encoded inside the mitochondrial genome, not the nuclear one. Current gray-market use is metabolic: fat loss, longevity, mitochondrial function. A growing use case is as a complement to GLP-1 drugs. “I’m on Ozempic but want to push further.”
The FDA has nominated two indications: obesity and osteoporosis. (Osteoporosis is bone-density loss severe enough to make bones fracture easily, common in post-menopausal women.) Obesity is straightforward: a patient with a BMI over 30 qualifies. Of three registered MOTs-C trials globally, one addresses obesity. Zero address osteoporosis.
The osteoporosis indication is worth watching for a reason that doesn’t turn on how the committee votes. FDA does not gatekeep patient diagnoses when it adds a substance to the 503A list. The listing describes the condition the substance was evaluated for, not the rule for which patients a licensed clinician can prescribe it to. Hormone-adjacent 503A compounds like DHEA, pregnenolone, and bioidentical hormone analogs have historically been prescribed well beyond the narrow evaluated indication, into perimenopausal symptoms, bone-health maintenance, and broader “anti-aging” territory. FDA has expressed concern about scope creep in past meetings but has not restricted prescribing at the patient-diagnosis level.
If MOTs-Cpasses for osteoporosis, the real addressable population probably isn’t just women with formal DEXA-diagnosed osteoporosis. It likely extends to osteopenia, the pre-osteoporotic stage that affects roughly forty to fifty percent of post-menopausal women, and to bone-health prescribing beyond that. The post-menopausal wellness space already spends heavily on exactly this kind of intervention.
If the vote passes, obese patients can legally get MOTs-C directly, and the osteoporosis indication would probably reach into the wider post-menopausal wellness market. That’s a population much larger than current gray-market users: millions of post-menopausal women whose physicians could newly prescribe. The vote itself is leaning no, though. The evidence base for both indications is thin, and the committee has never approved a systemic peptide.
Epitalon injection for anti-aging (sleep in practice)
Epitalon is a four-amino-acid peptide from a pineal-gland extract first characterized in the Soviet Union in the 1980s. It is marketed for anti-aging and telomere extension. The long-term studies that built its reputation, mostly by the Russian gerontologist Vladimir Anisimov, looked at lifespan in mice. Zero registered human clinical trials exist for Epitalon anywhere in the world.
The FDA is evaluating it for insomnia.
Whoever nominated Epitalon chose the single indication with some supporting human sleep data and avoided the anti-aging claim the agency would have rejected outright. But here is the thing most of the anti-aging marketing doesn’t tell you: most Epitalon users, whatever they believe about telomeres, describe sleep as the effect they actually notice. A patient walking into a post-approval pharmacy saying “I’ve been sleeping poorly” would qualify. A patient asking for Epitalon to live longer would not.
If the vote passes, most current users can legally get Epitalon, because most are already taking it for sleep effects even if they describe it as anti-aging. The insomnia indication also reaches a very large broader population of people with sleep problems. The vote is too close to call, leaning no.The scope-narrowing is clever. The evidence base is still thin. The committee’s posture is still skeptical.
What the pattern says
The FDA’s Pharmacy Compounding Advisory Committee has voted on 52 substance nominations over 15 years. Thirteen came back yes. Zero of those went to peptide compounds. That’s a 0% approval rate for the class, compared to roughly 25% for all substances. Topicals, vitamins, and amino acids have cleared at rates of 50 to 67 percent. Peptides run at zero.
Across the committee’s ten-year history, fifty-two substance ballots have been cast. Thirteen came back yes. Zero of those were peptides.
The committee approves about a quarter of substances overall, and roughly a third of the non-peptide substances it reviews. Topical compounds run at sixty-seven percent. Vitamins and minerals run at sixty-seven percent. Amino acids run at fifty percent. Steroid hormones run at fifty percent. Peptides run at zero.
The July vote is the first real test of whether that pattern breaks. KPV and Semaxare the compounds with the strongest individual case to be the first. Even an optimistic read shouldn’t exceed two yeses out of seven, and the approved indications would be narrower than how people actually use the compounds. Something real is happening in July. It is narrower and more uneven than “peptides are coming back,” but it is not nothing.
Will this vote help you?
What actually changes if any of this passes
A positive PCAC vote splits the market in two. It doesn’t close the gray one. For covered indications, access gets cleaner and more expensive: pharmacy-compounded peptides typically run 3 to 5 times the gray-market price. For uncovered indications (which is most of current use), having a legal channel tends to increase scrutiny of the gray-market one.
Whatever the vote totals look like, what actually changes for the people currently taking these compounds depends on which ones pass. Not how many. A yes on KPV and DSIP legitimizes access for a huge share of current users and opens the door to much larger populations of patients who aren’t on peptides today. A yes on BPC-157 and TB-500barely moves the needle for the populations actually taking them. One headline says “four of seven approved”; the reality is much more uneven.
The gray market does not disappear after a yes vote. It bifurcates. For covered uses, access gets cleaner, safer, and more expensive. Pharmacy-compounded peptides generally run three to five times the gray-market price. A gray-market BPC-157 vial at about fifty dollars becomes a pharmacy-compounded vial at about one hundred and seventy. An Epitalon vial at about seventy becomes about two hundred and eighty-five, the widest price gap of any compound on the agenda. For uncovered uses, the gray market gets worse. Legitimization of the approved channel raises enforcement pressure on the unapproved one, and off-label prescribing does not rescue anyone: for 503A compounded drugs, the pharmacy is bound by whatever qualifier FDA writes into the listing, and FDA consistently writes them. A doctor can still write BPC-157 for a torn tendon. No compliant pharmacy can legally fill it.
The breadth of the indication matters, though. A narrow indication like “ulcerative colitis” is hard to stretch; a patient clearly either qualifies or doesn’t. A broad indication like “inflammatory conditions” or “insomnia” leaves more room for clinical judgment, and historical precedent shows compounding pharmacies have let that room be used. Which is why the MOTs-C and KPV stories look different from the BPC-157 and TB-500 ones.
One more shift worth naming. Physicians who currently shrug or warn will have a real reason to learn, because they will have a compliant way to prescribe. Expect CME courses, peptide-focused clinics, and new telehealth services to scale within a year of any rule change. This is the quieter secondary consequence of July: not just new legal compounds, but a medical establishment suddenly incentivized to engage with them.
What’s not on the agenda
Seven peptides are at the July meeting. RFK Jr.’s “fourteen peptides” count included five that were removed from restricted status in 2024 through a legal settlement, without any PCAC review. Six others (CJC-1295, Ipamorelin, Thymosin Alpha-1, Selank, AOD-9604, and Kisspeptin-10) received unanimous or near-unanimous no votes at the 2024 PCAC sessions and are not on the July agenda.
Seven peptides are up for review. When HHS Secretary Robert F. Kennedy Jr. said on Joe Rogan in February that “fourteen peptides” were about to come back to legal status, he was referring to a different count. The gap between his fourteen and the committee’s seven is worth knowing about.
In September 2023, the FDA placed nineteen peptides on the restricted list. A year later, five were quietly removed after a nominator withdrew under a legal settlement: AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, and Selank. Removed, but not re-approved. They sit in a limbo the July meeting does not touch. This committee actually considered them at two separate meetings in 2024, October 29 and December 4, thirteen ballots in total. Every ballot came back no. Thymosin Alpha-1 drew four yes votes, the highest tally any peptide has received at PCAC, but even that was four against seventeen. The October and December hearings were populated by a small group of compounding-industry advocates, two compounders and one law firm, which tells you something about how concentrated the peptide-compounding world really is.
| Compound | Sep 2023 | Sep 2024 | Dec 2024 | Jul 2026 |
|---|---|---|---|---|
| BPC-157 | Cat. 2 | Cat. 2 | Cat. 2 | Review |
| KPV | Cat. 2 | Cat. 2 | Cat. 2 | Review |
| TB-500 | Cat. 2 | Cat. 2 | Cat. 2 | Review |
| MOTs-C | Cat. 2 | Cat. 2 | Cat. 2 | Review |
| DSIP | Cat. 2 | Cat. 2 | Cat. 2 | Review |
| Semax | Cat. 2 | Cat. 2 | Cat. 2 | Review |
| Epitalon | Cat. 2 | Cat. 2 | Cat. 2 | Review |
| Thymosin α-1 | Cat. 2 | Limbo | Rejected | Rejected |
| CJC-1295 | Cat. 2 | Limbo | Rejected | Rejected |
| Ipamorelin | Cat. 2 | Limbo | Rejected | Rejected |
| AOD-9604 | Cat. 2 | Limbo | Rejected | Rejected |
| Selank | Cat. 2 | Limbo | Rejected | Rejected |
| Kisspeptin-10 | Cat. 2 | Cat. 2 | Rejected | Rejected |
- Sep 202319 peptides placed on Category 2
- Sep 20245 peptides removed after nominator withdrawal
- Oct 2024PCAC rejects 5 peptide topics
- Dec 2024PCAC rejects 3 more
- Feb 2026Kennedy names "14 peptides" on Rogan
- Apr 2026July PCAC meeting announced
- Jul 2026PCAC reviews seven peptides
- Post-JulyFDA interim policy update
Track the full regulatory status of all 15 compounds in real time on the FDA Regulatory Tracker.
Kisspeptin-10, still on the restricted list, was also rejected in October. Even a clean yes sweep in July would leave seven compounds needing their own separate regulatory action to match the political framing.
What yes and no actually do
A positive PCAC recommendation is advisory rather than binding, but FDA has historically followed it. A yes vote moves a compound toward Category 1 status within weeks to months. A no vote places it on the FDA’s formal list of substances with significant safety concerns. For peptides, which have no supplement or other legal pathway, that typically closes access for the long term.
The vote is advisory. FDA is not legally bound by it, but historically the agency follows the committee. A yes moves toward Category 1 within weeks to months and final-rule status some time after that. A no moves the compound onto a formally titled list of “Other Bulk Drug Substances That May Present Significant Safety Risks.” For substances with another legal channel (dietary supplements, for example), that restriction doesn’t always bite. For peptides, which have no dietary-supplement pathway, it reliably does.
What to watch for, and when
The background materials will almost certainly be more informative than the meeting itself. How the FDA frames each case in writing is usually a better predictor of the vote than anything said on microphone on the day. The nominators for the July compounds are not public yet; they will be in those same background materials.
The real meaning of July
Whatever the vote totals look like, this is the first time a federal regulatory body has debated peptide compounding access in an open public session. The specific outcomes will be updated as votes happen. But the fact that this conversation is now on the record, with public comment, doesn’t change back. That shift is permanent regardless of how the votes go.
Whatever the vote totals look like on July 24, this meeting is the first concrete moment of a regulatory wave that has been building since Ozempic crossed into the mainstream. The GLP-1 drugs are peptides. The conversation they started is larger than them, and it has moved from gyms and podcasts into an open-session vote that will be transcribed and published. That shift is happening no matter which way the seven votes go.
The political backdrop is unusual. HHS has the authority to move peptides to Category 1 without waiting for the committee, and Kennedy’s February statement suggested they might. No such action has been taken between that statement and the meeting, which means the committee’s vote is the operative event. If that changes before July 23, the prediction changes with it.
The specific question on July 23 and 24 is narrower than the headlines suggest. Seven peptides, seven indications. The committee will answer whether each compound works for the condition FDA chose before the meeting opened. What people actually take these compounds for, and whether the evidence supports those uses, is a different question. The committee won’t ask it. The decade will.
At a glance: the seven
Evidence grades on the individual compound pages are the fuller picture. Individual responses depend on dosing, health status, and the specific condition.
| Compound | FDA is evaluating | Community use | Prediction |
|---|---|---|---|
| KPV | Wound healing, inflammatory conditions | IBD, inflammatory skin, general inflammation | Likely yes |
| DSIP (Emideltide) | Opioid withdrawal, chronic insomnia, narcolepsy | Sleep | Likely no on evidence |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Cognitive performance | Narrow yes, or close |
| Epitalon | Insomnia | Marketed as anti-aging; effect users notice is sleep | Too close to call, leaning no |
| MOTs-C | Obesity, osteoporosis | Metabolic, GLP-1 complement | Likely no on evidence |
| BPC-157 | Ulcerative colitis | Musculoskeletal injury | Likely no |
| TB-500 | Wound healing | Injury recovery, systemic repair | Likely no |
✦ July 2026 PCAC
Questions worth knowing the answers to.
The Pharmacy Compounding Advisory Committee advises FDA on which bulk drug substances may be used in compounded medications. In July 2026 it will review seven peptides: BPC-157, KPV, TB-500, MOTS-C, Emideltide (DSIP), Semax, and Epitalon. The question is whether each should be added to the 503A Bulks List for patient-specific compounding.
The Pep Dispatch
Get evidence-based peptide research, twice a month.
Subscribe to find out what.
Next dispatch · May 2026 · Honest frequency: a few times a month